Drug intelligence / Profile preview

propofol + alfentanil + lidocaine

Development stage
Unknown
Lead developer
AkzoNobel
Modality
Peptides, Small Molecules
Administration
Intravenous
01

Overview

This is a combination of three pharmaceutical agents—propofol, alfentanil, and lidocaine—used together primarily for induction and maintenance of anesthesia or sedation during surgical or diagnostic procedures. - **Propofol** is an intravenous general anesthetic that acts as a positive allosteric modulator at the gamma-aminobutyric acid type A (GABA-A) receptor, enhancing inhibitory neurotransmission in the central nervous system to produce hypnosis and sedation[6][7][8]. - **Alfentanil** is a potent, short-acting synthetic opioid analgesic that acts as an agonist at the mu-opioid receptor, providing rapid-onset analgesia and supplementing anesthesia[1][2][3]. - **Lidocaine** is an amide-type local anesthetic that blocks voltage-gated sodium channels in neuronal membranes, inhibiting nerve impulse conduction to provide local anesthesia and reduce pain associated with propofol injection[5]. The combination leverages synergistic effects for improved intubating conditions, enhanced sedation/analgesia, reduced pain on injection (from propofol), and potentially lower doses of each agent compared to monotherapy. This mixture has been studied for use in both adult and pediatric populations undergoing various procedures requiring general anesthesia or deep sedation[1][2][3][5].

02

Targets

MOR (Mu opioid receptor)NaV (Voltage-gated sodium channels)GABRR (GABA-A receptor subunit rho)

Beyond the preview

Go deeper on propofol + alfentanil + lidocaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on propofol + alfentanil + lidocaine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call